Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 256-360-6
CAS number: 48145-04-6
Number of mated females
Number of pregnant females
The following females were not pregnant:
Group 1: 4 and 7
Group 2: 31, 33, 34, 39, 40, 42, 48 and
Group 3: 61, 62, 64, 74, 78, 79, 87 and
Group 4: 92, 97, 98 and 109.
The toxicity and adverse effects of 2-phenoxyethyl acrylate on
prenatal development toxicity were investigated in accordance with the
requirements of OECD 414 test guideline.
2-phenoxyethyl acrylate was administered by oral gavage to four
groups (0, 65, 200, and 600 mg/kg bw/day), each of 22-29 female rats.
Treatment started at Day 6 post coitum and ended at Day 19 post coitum.
At day 20 post coitum caesarean section and necropsy were performed.
The administration with 2-Phenoxyethyl Acrylate by oral gavage,
did not cause mortality, changes in body-weight and food consumption and
caused no adverse clinical signs at any of the doses. Salivation
recorded at 600 mg/kg/ bw/day was attributable to the palatability of
the test item. A slightly increased post implantation loss of 12.2% was
observed at 600 mg/kg bw/d compared to control group (8.3%). However,
the available historical control data (2014-2016), indicated a
considerable lower mean incidence of post implantation losses of 3.1%.
There were no test-item related changes in the observations
derived from hysterectomy. The skeletal examination of the fetuses
showed a slightly increased incidence in incomplete ossification
considered a transient stage in fetal development. As this finding is
expected to be resolved in time, this finding is not considered adverse.
The slightly increased incidence of fused/partially fused maxilla/jugal
(precocious ossification) is not considered to be relevant, as it was
only recorded at the low dose (65 mg/kg/ bw/day). The external, skeletal
and visceral examination of the fetuses showed the presence of major
abnormalities in two fetuses (no. 9 from the litters no. 12 and 13) from
the Control group, two fetuses (no. 6 and 12 from litter 68) at 200
mg/kg/ bw/day and two fetuses (no. 5 from litter 103 and no. 1 from
litter 94) at the dose of 600 mg/kg/ bw/day. Despite the fact that these
abnormalities were also observed in some of the groups treated with the
test item, the incidence and distribution recorded could be considered
It should be noted that a higher dose level than 600 mg/kg bw/d
(with a higher potential for systemic uptake and systemic toxicity)
could not be used for this study due to the observations in the dose
range finding study where severe local irritation in the stomach was
observed at 300 and 800 mg/kg bw/d.
In conclusion, as the increase in postimplantation loss was not
significant at the dose level of 600 mg/kg/ bw/d, a formal NOAEL for
maternel toxicity as well as for fertility/developmental toxicity of 600
mg/kg bw/d can be concluded in this study when assessed on its own.
However, as postimplantation loss has also been seen in the dose-range
finding study and in the OECD 422 study at a dose level of 800 mg/kg
bw/d the postimplantation loss at 600 mg/kg bw/d in this OECD 414 study
may be considered related to the dosing and thus, a more precautious
NOAEL of 200 mg/kg bw/d for increased postimplantation loss may be
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again